Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arbutus Biopharma Corporation (NASDAQ: ABUS).

Full DD Report for ABUS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABUS)

Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib
Stock Monitor: Arbutus Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ), all you need to do is sign up now by clicking the following link www.active-investors.com/registr...
Source: ACCESSWIRE IA
Date: May, 07 2018 07:10
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call Transcript
Arbutus Biopharma Corp. (ABUS) Q1 2018 Earnings Conference Call May 03, 2018 04:30 PM ET Executives Tiffany Tolmie - Manager, Investor Relations Mark Murray - Chief Executive Officer William Symonds - Chief Development Officer Koert VandenEnden - Interim CFO Analysts Kath...
Source: SeekingAlpha
Date: May, 06 2018 13:15
Arbutus Biopharma beats by $0.03, beats on revenue
Arbutus Biopharma (NASDAQ: ABUS ): Q1 EPS of -$0.36 beats by $0.03 . More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:14
Arbutus Announces Corporate Update and First Quarter 2018 Financial Results
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA Therapeutics Company Company to Host a Corporate Update Conference Call Today at ...
Source: GlobeNewswire
Date: May, 03 2018 16:00
Eidos Therapeutics commences mid-stage study of lead drug in ATTR
Privately held Eidos Therapeutics announces that the first patient has been dosed in a Phase 2 clinical trial assessing lead candidate AG10 in patients with symptomatic transthyretin amyloidosis (ATTR) cardiomyopathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals...
Source: SeekingAlpha
Date: May, 03 2018 09:55
Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM...
Source: GlobeNewswire
Date: April, 30 2018 09:00
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy Results Subcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia and WARMINSTER, Pa., April 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ...
Source: GlobeNewswire
Date: April, 12 2018 12:00
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos, former CEO of ARIAD Pharmaceuticals through it...
Source: GlobeNewswire
Date: April, 11 2018 17:24
New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Talend S.A. (NASDAQ:TLND), Chipmos Technologies Ltd. (NASDAQ:IMOS), POSC...
Source: GlobeNewswire
Date: April, 11 2018 08:20
RNAi For Hepatitis B - A False Hope For A Cure?
Editor's note: Seeking Alpha is proud to welcome BZ Equity Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Hepat...
Source: SeekingAlpha
Date: April, 06 2018 14:59

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-159.108.909.208.80140,048
2018-08-149.609.209.858.85325,731
2018-08-139.709.67510.309.35397,134
2018-08-099.409.759.9259.30246,526
2018-08-089.609.5759.709.40168,478

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-159,86036,03527.3623Cover
2018-08-1424,02551,68246.4862Short
2018-08-1342,817101,78742.0653Short
2018-08-1048,238103,78546.4788Short
2018-08-0969,39690,24576.8973Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABUS.


About Arbutus Biopharma Corporation (NASDAQ: ABUS)

Logo for Arbutus Biopharma Corporation (NASDAQ: ABUS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ABUS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 23 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 12 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: March, 16 2018

       

       


      Daily Technical Chart for (NASDAQ: ABUS)

      Daily Technical Chart for (NASDAQ: ABUS)


      Stay tuned for daily updates and more on (NASDAQ: ABUS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ABUS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ABUS and does not buy, sell, or trade any shares of ABUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/